Skip to main content
SpringerLink
Log in

The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs

  • Research Article
  • Theme: Develop Enabling Technologies for Delivering Poorly Water Soluble Drugs: Current Status and Future Perspectives
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

While each of the two key parameters of oral drug absorption, the solubility and the permeability, has been comprehensively studied separately, the relationship and interplay between the two have been largely ignored. For instance, when formulating a low-solubility drug using various solubilization techniques: what are we doing to the apparent permeability when we increase the solubility? Permeability is equal to the drug’s diffusion coefficient through the membrane times the membrane/aqueous partition coefficient divided by the membrane thickness. The direct correlation between the intestinal permeability and the membrane/aqueous partitioning, which in turn is dependent on the drug’s apparent solubility in the GI milieu, suggests that the solubility and the permeability are closely associated, exhibiting a certain interplay between them, and the current view of treating the one irrespectively of the other may not be sufficient. In this paper, we describe the research that has been done thus far, and present new data, to shed light on this solubility–permeability interplay. It has been shown that decreased apparent permeability accompanies the solubility increase when using different solubilization methods. Overall, the weight of the evidence indicates that the solubility–permeability interplay cannot be ignored when using solubility-enabling formulations; looking solely at the solubility enhancement that the formulation enables may be misleading with regards to predicting the resulting absorption, and hence, the solubility–permeability interplay must be taken into account to strike the optimal solubility–permeability balance, in order to maximize the overall absorption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Lennernas H. Human intestinal permeability. J Pharm Sci. 1998;87(4):403–10. doi:10.1021/js970332a.

    Article  PubMed  CAS  Google Scholar 

  2. Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev. 1996;19(3):359–76. doi:10.1016/0169-409x(96)00009-9.

    Article  PubMed  CAS  Google Scholar 

  3. Sun D, Yu LX, Hussain MA, Wall DA, Smith RL, Amidon GL. In vitro testing of drug absorption for drug ‘developability’ assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel. 2004;7(1):75–85.

    PubMed  CAS  Google Scholar 

  4. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413.

    Article  PubMed  CAS  Google Scholar 

  5. Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharmaceutics. 2009;6(1):19–28. doi:10.1021/mp800088f.

    Article  CAS  Google Scholar 

  6. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J. 2009;11(4):740–6. doi:10.1208/s12248-009-9144-x.

    Article  PubMed  CAS  Google Scholar 

  7. Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, Lennernas H, et al. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharmaceutics. 2010;7(5):1827–34. doi:10.1021/mp100175a.

    Article  CAS  Google Scholar 

  8. Lennernas H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol. 1997;49(7):627–38. doi:10.1111/j.2042-7158.1997.tb06084.x.

    Article  PubMed  CAS  Google Scholar 

  9. Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50(1):3–12.

    Article  PubMed  CAS  Google Scholar 

  10. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42(6):620–43.

    Article  PubMed  CAS  Google Scholar 

  11. Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res. 2006;23(9):2165–74. doi:10.1007/s11095-006-9054-x.

    Article  PubMed  CAS  Google Scholar 

  12. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129(1):1–10. doi:10.1016/j.jconrel.2008.03.021.

    Article  PubMed  CAS  Google Scholar 

  13. Gao Y, Carr RA, Spence JK, Wang WW, Turner TM, Lipari JM, et al. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling. Mol Pharmaceutics. 2010;7(5):1516–26. doi:10.1021/mp100157s.

    Article  CAS  Google Scholar 

  14. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26. doi:10.1016/s0169-409x(00)00129-0.

    Article  PubMed  CAS  Google Scholar 

  15. Stenberg P, Bergström CAS, Luthman K, Artursson P. Theoretical predictions of drug absorption in drug discovery and development. Clin Pharmacokinet. 2002;41(11):877–99.

    Article  PubMed  CAS  Google Scholar 

  16. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59(7):645–66. doi:10.1016/j.addr.2007.05.012.

    Article  PubMed  CAS  Google Scholar 

  17. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3(12):1023.

    Article  PubMed  CAS  Google Scholar 

  18. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017–25.

    Article  PubMed  CAS  Google Scholar 

  19. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci. 1996;85(11):1142–69.

    Article  PubMed  CAS  Google Scholar 

  20. Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release. 2007;123(2):78.

    Article  PubMed  CAS  Google Scholar 

  21. Loftsson T, Vogensen SB, Brewster ME, Konráðsdóttir F. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci. 2007;96(10):2532–46. doi:10.1002/jps.20992.

    Article  PubMed  CAS  Google Scholar 

  22. Loftsson T, Jarho P, Másson M, Järvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv. 2005;2(2):335–51. doi:10.1517/17425247.2.1.335.

    Article  PubMed  CAS  Google Scholar 

  23. Loftsson T, Brewster ME, Masson M. Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv. 2004;2(4):261.

    Article  CAS  Google Scholar 

  24. Rao VM, Stella VJ. When can cyclodextrins be considered for solubilization purposes? J Pharm Sci. 2003;92(5):927–32.

    Article  PubMed  CAS  Google Scholar 

  25. Miller LA, Carrier RL, Ahmed I. Practical considerations in development of solid dosage forms that contain cyclodextrin. J Pharm Sci. 2007;96(7):1691–707.

    Article  PubMed  CAS  Google Scholar 

  26. Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL. The solubility–permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci. 2010;99(6):2739–49. doi:10.1002/jps.22033.

    PubMed  CAS  Google Scholar 

  27. Gamsiz E, Miller L, Thombre A, Ahmed I, Carrier RL. Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development. Biotech Bioeng. 2010;105(2):409–20.

    Article  CAS  Google Scholar 

  28. Gamsiz E, Thombre A, Ahmed I, Carrier RL. Drug salts and solubilization: modeling the influence of cyclodextrins on oral absorption. Ann Biomed Eng. 2011;39(1):455–68. doi:10.1007/s10439-010-0169-1.

    Article  PubMed  Google Scholar 

  29. Gamsiz ED, Miller L, Thombre AG, Ahmed I, Carrier RL. Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation. Biotechnol Bioeng. 2010;105(2):421–30. doi:10.1002/bit.22524.

    Article  PubMed  CAS  Google Scholar 

  30. Brewster ME, Noppe M, Peeters J, Loftsson T. Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins. Int J Pharm. 2007;342(1–2):250–3. doi:10.1016/j.ijpharm.2007.04.029.

    Article  PubMed  CAS  Google Scholar 

  31. Amidon GE, Higuchi WI, Ho NFH. Theoretical and experimental studies of transport of micelle-solubilized solutes. J Pharm Sci. 1982;71(1):77–84. doi:10.1002/jps.2600710120.

    Article  PubMed  CAS  Google Scholar 

  32. Katneni K, Charman SA, Porter CJH. Permeability assessment of poorly water-soluble compounds under solubilizing conditions: the reciprocal permeability approach. J Pharm Sci. 2006;95(10):2170–85. doi:10.1002/jps.20687.

    Article  PubMed  CAS  Google Scholar 

  33. Katneni K, Charman SA, Porter CJH. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J Pharm Sci. 2007;96(2):280–93. doi:10.1002/jps.20779.

    Article  PubMed  CAS  Google Scholar 

  34. Katneni K, Charman SA, Porter CJH. Use of plasma proteins as solubilizing agents in in vitro permeability experiments: correction for unbound drug concentration using the reciprocal permeability approach. J Pharm Sci. 2008;97(1):209–24. doi:10.1002/jps.20877.

    Article  PubMed  CAS  Google Scholar 

  35. Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, Amidon GL, Dahan A. The solubility–permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharmaceutics. 2011;8(5):1848–56. doi:10.1021/mp200181v.

    Article  CAS  Google Scholar 

  36. Mudra DR, Borchardt RT. Absorption barriers in the rat intestinal mucosa. 3: effects of polyethoxylated solubilizing agents on drug permeation and metabolism. J Pharm Sci. 2010;99(2):1016–27. doi:10.1002/jps.21836.

    PubMed  CAS  Google Scholar 

  37. Mudra DR, Borchardt RT. Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism. J Pharm Sci. 2010;99(2):982–98. doi:10.1002/jps.21912.

    PubMed  CAS  Google Scholar 

  38. Mudra DR, Jin JY, Borchardt RT. Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism. J Pharm Sci. 2010;99(2):999–1015. doi:10.1002/jps.21965.

    PubMed  CAS  Google Scholar 

  39. Nerurkar MM, Ho NFH, Burton PS, Vidmar TJ, Borchardt RT. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci. 1997;86(7):813–21. doi:10.1021/js960483y.

    Article  PubMed  CAS  Google Scholar 

  40. Poelma FGJ, Breäs R, Tukker JJ. Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat. Pharm Res. 1990;7(4):392–7. doi:10.1023/a:1015827624296.

    Article  PubMed  CAS  Google Scholar 

  41. Poelma FGJ, Breäs R, Tukker JJ, Crommelin DJA. Intestinal absorption of drugs. The influence of mixed micelles on the disappearance kinetics of drugs from the small intestine of the rat. J Pharm Pharmacol. 1991;43(5):317–24. doi:10.1111/j.2042-7158.1991.tb06697.x.

    Article  PubMed  CAS  Google Scholar 

  42. Yano K, Masaoka Y, Kataoka M, Sakuma S, Yamashita S. Mechanisms of membrane transport of poorly soluble drugs: role of micelles in oral absorption processes. J Pharm Sci. 2010;99(3):1336–45. doi:10.1002/jps.21919.

    Article  PubMed  CAS  Google Scholar 

  43. Buyukozturk F, Benneyan JC, Carrier RL. Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. J Control Release. 2010;142(1):22–30. doi:10.1016/j.jconrel.2009.10.005.

    Article  PubMed  CAS  Google Scholar 

  44. Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm. 2007;67(1):96–105. doi:10.1016/j.ejpb.2007.01.017.

    Article  PubMed  CAS  Google Scholar 

  45. Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36.

    Article  PubMed  CAS  Google Scholar 

  46. Riad LE, Sawchuk RJ. Effect of polyethylene glycol 400 on the intestinal permeability of carbamazepine in the rabbit. Pharm Res. 1991;8(4):491–7. doi:10.1023/a:1015803312233.

    Article  PubMed  CAS  Google Scholar 

  47. Miller JM, Beig A, Carr RA, Webster GK, Dahan A. The solubility–permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. Mol Pharmaceutics. 2012. doi:10.1021/mp200460u.

  48. Beig A, Miller JM, Dahan A. Accounting for the solubility–permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption. Eur J Pharm Biopharm. 2012. doi:10.1016/j.ejpb.2012.02.012.

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva, 84105, Israel

    Arik Dahan

  2. Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, 60064, USA

    Jonathan M. Miller

Authors
  1. Arik Dahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan M. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arik Dahan.

Additional information

Guest Editors: Ping Gao and Lawrence Yu

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dahan, A., Miller, J.M. The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs. AAPS J 14, 244–251 (2012). https://doi.org/10.1208/s12248-012-9337-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-012-9337-6

KEY WORDS

Search

Navigation